Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Flu Vaccines
HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza a (H1N1)
June 17th, 2009
MedImmune announced that the U.S. Department of Health and Human Services (HHS) has awarded the company a contract to manufacture monovalent (single-strain) live attenuated influenza vaccine for Novel Influenza A (H1N1) to vaccinate priority populations identified by HHS in the National Strategy for Pandemic Influenza. An initial order of $90 million of vaccine has been placed, with the potential for additional orders. This project has been funded in whole or in part with the Federal funds from HHS/ASPR/BARDA, under Contract No. HHSO100200900002I. MedImmune scientists have identified several promising vaccine candidates against the Novel Influenza A (H1N1) strain, and...
Source: Vaccine Weekly (2009-06-17)
|
